![Ian-Chau](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/video/patients-with-advanced-gastric-cancer-benefit-from-perioperative-chemotherapy-in-two-studies/8738092-3-eng-GB/patients-with-advanced-gastric-cancer-benefit-from-perioperative-chemotherapy-in-two-studies_i770.png)
![Ian-Chau](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/video/patients-with-advanced-gastric-cancer-benefit-from-perioperative-chemotherapy-in-two-studies/8738092-3-eng-GB/patients-with-advanced-gastric-cancer-benefit-from-perioperative-chemotherapy-in-two-studies_i770.png)
![ESMO 2019-Tumour mutational burden_NSCLC|ESMO 2019-Tumour mutational burden_NSCLC](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/is-tissue-tumour-mutational-burden-a-predictive-biomarker-for-immunotherapy-in-lung-cancer/8735248-3-eng-GB/is-tissue-tumour-mutational-burden-a-predictive-biomarker-for-immunotherapy-in-lung-cancer_i770.jpg)
Is tissue tumour mutational burden a predictive biomarker for immunotherapy in lung cancer?
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
![ESMO 2019_FGFR_cholangiocarcinoma](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/precision-medicine-bursts-onto-the-biliary-tract-cancer-scene/8735317-3-eng-GB/precision-medicine-bursts-onto-the-biliary-tract-cancer-scene_i770.jpg)
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies
![ESMO 2019 Barcelona](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2019/articles/anlotinib-improves-overall-survival-in-relapsed-sclc/8734489-3-eng-GB/anlotinib-improves-overall-survival-in-relapsed-sclc_i770.jpg)
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer